ArriVent BioPharma financials
$29.54+0.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$177.5M | -$94.3M |
| Net income | -$166.3M | -$80.5M |
| Net margin | — | — |
| Diluted EPS | $-4.32 | $-2.56 |
| EBITDA | -$180.6M | -$94.3M |
| Operating cash flow | -$160.6M | -$70.2M |
| Free cash flow | -$160.6M | -$70.2M |
| Diluted shares | 38.5M | 31.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $45.5M | $74.3M |
| Short-term investments | $267.3M | $144.6M |
| Total debt | $0.00 | $0.00 |
| Total assets | $333.2M | $274.9M |
| Total liabilities | $25.9M | $17.3M |
| Shareholders' equity | $307.2M | $257.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology